
VACV Protein OPG176 142-150, GLFDFVNFV
Description
About VACV Protein OPG176 142-150, GLFDFVNFV
The Vaccinia virus (VACV) Protein OPG 176 Peptide (IEDB: 20833) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Protein OPG Peptide, H-GLFDFVNFV-OH (Uniprot: P26672 aa: 142-150) from JPT is produced under strict quality control and quality management.
VACV Protein OPG176 142-150, GLFDFVNFV - Specifications
- Peptide sequence: H-GLFDFVNFV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Infection
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for VACV Protein OPG176 142-150, GLFDFVNFV
References:
Read References with JPT’s Antigen Peptides
VACV Protein OPG176 142-150, GLFDFVNFV has been described in:
HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products., J Immunol, 2005 (PMID: 16210659)
Identification of HLA class I restricted epitopes derived from variola and vaccinia viruses, nan, 2006 (PMID: Submission)
Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination., Sci Rep, 2017 (PMID: 28386132)
Documentation
Documentation for VACV Protein OPG176 142-150, GLFDFVNFV
Properties
Properties of VACV Protein OPG176 142-150, GLFDFVNFV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Infection |
Layout: | Freeze-dried in glass vial |
Organism: | Vaccinia virus (VACV) |
Protein Name: | Protein OPG |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to VACV Protein OPG176 142-150, GLFDFVNFV
Information | Values |
---|---|
Sequence: | H-GLFDFVNFV-OH |
Specifications: | 9mer peptide as TFA salt |